RT Journal Article
SR Electronic
T1 Predicting non-response to ketamine for depression: a symptom-level analysis of real-world data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.03.23292094
DO 10.1101/2023.07.03.23292094
A1 Miller, Eric A.
A1 Afshar, Houtan Totonchi
A1 Mishra, Jyoti
A1 Ramanathan, Dhakshin
YR 2023
UL http://medrxiv.org/content/early/2023/07/05/2023.07.03.23292094.abstract
AB Background Ketamine helps some patients with treatment resistant depression (TRD), but reliable methods for predicting which patients will, or will not, respond to treatment are lacking.Methods This is a retrospective analysis of PHQ-9 item response data from 120 military veterans with TRD who received repeated doses of intravenous racemic ketamine or intranasal eskatamine in a real-world clinic. Regression models were fit to individual patients’ symptom trajectories and model parameters were analyzed to characterize how different symptoms responded to treatment. Logistic regression classifiers were used to predict treatment response using patients’ baseline depression symptoms alone. Finally, by parametrically adjusting the classifier decision thresholds, the full space of models was searched to identify the best models for predicting non-response with very high negative predictive value.Results Model slopes indicated progressive improvement on all nine symptoms, but the symptom of depressed mood improved faster than the symptom of low energy. The first principal component (PC) represented a data-driven measurement of overall treatment response, while the second PC divided the symptoms into affective and somatic subdomains. Logistic regression classifiers predicted response better than chance using baseline symptoms, but these models achieved only 60.2% predictive value. Using threshold tuning, we identified models that can predict non-response with a negative predictive value of 96.4%, while retaining a specificity of 22.1%, suggesting we could successfully identify 22% of individuals who would not respond purely based on baseline symptom scores.Conclusions We developed an approach for identifying a subset of patients with TRD who will likely not respond to ketamine. This could inform rational treatment recommendations to avoid additional treatment failures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Ramanathan is supported by funding from the Center of Excellence for Stress and Mental Health, Burroughs Wellcome Fund, Career Award for Medical Scientists.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board (IRB) of the VA San Diego Healthcare System approved this study as an IRB exemption (IRB 1223219).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors